ロード中...
Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression
Drug resistance, a major obstacle to successful cancer chemotherapy, frequently occurs in recurrent or metastatic breast cancer and results in poor clinical response. Fulvestrant is a new type of selective estrogen receptor (ER) downregulator and a promising endocrine therapy for breast cancer. In t...
保存先:
| 出版年: | Oncol Rep |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5355712/ https://ncbi.nlm.nih.gov/pubmed/28000875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2016.5315 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|